目的:探讨双特异性酪氨酸磷酸化调节激酶2(dual-specificity tyrosine phosphorylation-regulated kinase2,DYRK2)在胰腺癌中的表达及其临床意义.方法:应用实时荧光定量PCR、Western blot及免疫组织化学技术检测40例胰腺癌及其癌旁正常...目的:探讨双特异性酪氨酸磷酸化调节激酶2(dual-specificity tyrosine phosphorylation-regulated kinase2,DYRK2)在胰腺癌中的表达及其临床意义.方法:应用实时荧光定量PCR、Western blot及免疫组织化学技术检测40例胰腺癌及其癌旁正常组织标本中DYRK2mRNA和蛋白的表达量,并结合免疫组织化学结果及胰腺癌患者的临床病理资料进行统计学分析.结果:实时荧光定量PCR检测显示,DYRK2m R N A在胰腺癌及其癌旁组织中均有表达,但后者的表达水平明显高于前者(P<0.01);Western blot检测显示,在88.9%的癌组织中D Y R K2蛋白的表达量低于其对应的癌旁组织;免疫组织化学染色显示,DYRK2在胰腺癌组织中的阳性比例明显低于其癌旁组织(42.5%vs87.5%,X2=17.802,P<0.01),且DYRK2的表达与胰腺癌有无淋巴结转移相关(X2=6.32,P<0.05).结论:DYRK2在胰腺癌组织中表达下调,可能与胰腺癌的发生发展和淋巴结转移等恶性生物学行为相关.展开更多
Background: Previously, we reported that dual-specificity adenocarcinoma (EEA). However, the role of DUSP1 medroxyprogesterone (MPA) are still unclear. phosphatase I (DUSPI) was differentially expressed in endo...Background: Previously, we reported that dual-specificity adenocarcinoma (EEA). However, the role of DUSP1 medroxyprogesterone (MPA) are still unclear. phosphatase I (DUSPI) was differentially expressed in endometrioid in EEA progression and the relationship between DUSPI and Methods: The expression of DUSPI in EEA specimens was detected by immunohistochemical analysis. The effect of DUSPI on cell proliferation was analyzed by Cell Counting Kit 8 and colony formation assay, and cell migration was analyzed by transwell assay. MPA-induced DUSPI expression in EEA cells was measured by Western blot. Results: DUSPI expression was deficient in advanced International Federation of Gynecology and Obstetrics stage, high-grade and myometrial invasive EEA. In EEA cell lines (HeclA, Hecl B, RL952, and Ishikawa), the DUSP1 expression was substantially higher in lshikawa cells than in other cell lines (P 〈 0.05). Knockdown ofDUSP I promoted lshikawa cells proliferation, migration, and activation of mitogen-activated protein kinases/extracellular signal-regulated kinase (MAPK/Erk) pathway. MPA-induced DUSP1 expression and inhibited MAPK/Erk pathway in Ishikawa cells. Conclusions: Our data suggest that DUSP1 deficiency promotes EEA progression via MAPK/Erk pathway, which may be reversed by MPA, suggesting that DUSP I may serve as a potential therapeutic target for the treatment of EEA.展开更多
文摘目的:探讨双特异性酪氨酸磷酸化调节激酶2(dual-specificity tyrosine phosphorylation-regulated kinase2,DYRK2)在胰腺癌中的表达及其临床意义.方法:应用实时荧光定量PCR、Western blot及免疫组织化学技术检测40例胰腺癌及其癌旁正常组织标本中DYRK2mRNA和蛋白的表达量,并结合免疫组织化学结果及胰腺癌患者的临床病理资料进行统计学分析.结果:实时荧光定量PCR检测显示,DYRK2m R N A在胰腺癌及其癌旁组织中均有表达,但后者的表达水平明显高于前者(P<0.01);Western blot检测显示,在88.9%的癌组织中D Y R K2蛋白的表达量低于其对应的癌旁组织;免疫组织化学染色显示,DYRK2在胰腺癌组织中的阳性比例明显低于其癌旁组织(42.5%vs87.5%,X2=17.802,P<0.01),且DYRK2的表达与胰腺癌有无淋巴结转移相关(X2=6.32,P<0.05).结论:DYRK2在胰腺癌组织中表达下调,可能与胰腺癌的发生发展和淋巴结转移等恶性生物学行为相关.
文摘Background: Previously, we reported that dual-specificity adenocarcinoma (EEA). However, the role of DUSP1 medroxyprogesterone (MPA) are still unclear. phosphatase I (DUSPI) was differentially expressed in endometrioid in EEA progression and the relationship between DUSPI and Methods: The expression of DUSPI in EEA specimens was detected by immunohistochemical analysis. The effect of DUSPI on cell proliferation was analyzed by Cell Counting Kit 8 and colony formation assay, and cell migration was analyzed by transwell assay. MPA-induced DUSPI expression in EEA cells was measured by Western blot. Results: DUSPI expression was deficient in advanced International Federation of Gynecology and Obstetrics stage, high-grade and myometrial invasive EEA. In EEA cell lines (HeclA, Hecl B, RL952, and Ishikawa), the DUSP1 expression was substantially higher in lshikawa cells than in other cell lines (P 〈 0.05). Knockdown ofDUSP I promoted lshikawa cells proliferation, migration, and activation of mitogen-activated protein kinases/extracellular signal-regulated kinase (MAPK/Erk) pathway. MPA-induced DUSP1 expression and inhibited MAPK/Erk pathway in Ishikawa cells. Conclusions: Our data suggest that DUSP1 deficiency promotes EEA progression via MAPK/Erk pathway, which may be reversed by MPA, suggesting that DUSP I may serve as a potential therapeutic target for the treatment of EEA.